Literature DB >> 14604968

The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients.

Gal Markel1, Huda Mussaffi, Khoon-Lin Ling, Mariolina Salio, Stephan Gadola, Guy Steuer, Hannah Blau, Hagit Achdout, María de Miguel, Tsufit Gonen-Gross, Jacob Hanna, Tal I Arnon, Udi Qimron, Ilan Volovitz, Lea Eisenbach, Richard S Blumberg, Angel Porgador, Vincenzo Cerundolo, Ofer Mandelboim.   

Abstract

The killing of natural killer (NK) cells is regulated by activating and inhibitory NK receptors that recognize mainly class I major histocompatibility complex (MHC) proteins. In transporter associated with antigen processing (TAP2)-deficient patients, killing of autologous cells by NK cells is therefore expected. However, none of the TAP2-deficient patients studied so far have suffered from immediate NK-mediated autoimmune manifestations. We have previously demonstrated the existence of a novel class I MHC-independent inhibitory mechanism of NK cell cytotoxicity mediated by the homophilic carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) interactions. Here, we identified 3 new siblings suffering from TAP2 deficiency. NK cells derived from these patients express unusually high levels of the various killer cell inhibitory receptors (KIRs) and the CEACAM1 protein. Importantly, the patients' NK cells use the CEACAM1 protein to inhibit the killing of tumor and autologous cells. Finally, we show that the function of the main NK lysis receptor, NKp46, is impaired in these patients. These results indicate that NK cells in TAP2-deficient patients have developed unique mechanisms to reduce NK killing activity and to compensate for the lack of class I MHC-mediated inhibition. These mechanisms prevent the attack of self-cells by the autologous NK cells and explain why TAP2-deficient patients do not suffer from autoimmune manifestations in early stages of life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604968     DOI: 10.1182/blood-2003-06-2114

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

Review 2.  Emerging insights into human health and NK cell biology from the study of NK cell deficiencies.

Authors:  Emily M Mace; Jordan S Orange
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

Review 3.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

4.  Novel APC-like properties of human NK cells directly regulate T cell activation.

Authors:  Jacob Hanna; Tsufit Gonen-Gross; Jonathan Fitchett; Tony Rowe; Mark Daniels; Tal I Arnon; Roi Gazit; Aviva Joseph; Karoline W Schjetne; Alexander Steinle; Angel Porgador; Dror Mevorach; Debra Goldman-Wohl; Simcha Yagel; Michael J LaBarre; Jane H Buckner; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 5.  The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.

Authors:  Uwe Rueckschloss; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2016-09-30       Impact factor: 4.304

6.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

7.  CD66a (CEACAM1) expression by mouse natural killer cells.

Authors:  Gaëtan Thirion; Ana Agusti Feliu; Jean-Paul Coutelier
Journal:  Immunology       Date:  2008-05-17       Impact factor: 7.397

Review 8.  Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators.

Authors:  Hussam Baghdadi; Nada Abdel-Aziz; Nagwa Sayed Ahmed; Hany Salah Mahmoud; Ayman Barghash; Abdullah Nasrat; Manal Mohamed Helmy Nabo; Salah Mohamed El Sayed
Journal:  Int J Health Sci (Qassim)       Date:  2015-04

9.  CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling.

Authors:  Shuhei Hosomi; Zhangguo Chen; Kristi Baker; Lanfen Chen; Yu-Hwa Huang; Torsten Olszak; Sebastian Zeissig; Jing H Wang; Ofer Mandelboim; Nicole Beauchemin; Lewis L Lanier; Richard S Blumberg
Journal:  Eur J Immunol       Date:  2013-06-18       Impact factor: 5.532

10.  Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.

Authors:  Gal Markel; Rachel Seidman; Yifat Cohen; Michal J Besser; Tali Cohen Sinai; Avraham J Treves; Arie Orenstein; Raanan Berger; Jacob Schachter
Journal:  Immunology       Date:  2008-06-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.